Completed PHASE1 INTERVENTIONAL 4-arm NCT00386490

Safety of Larazotide Acetate in Healthy Volunteers

A Phase 1, Randomized, Double-Blind, Placebo Controlled, Multi-Dose Study to Determine the Safety, Tolerance and Pharmacokinetics of 3 Dose Levels of Larazotide Acetate (AT-1001) in Healthy Volunteers

Sponsor: 9 Meters Biopharma, Inc.

Conditions Healthy

Interventions larazotide acetate

Updated 7 times since 2017 Last updated: Sep 8, 2017 Started: Jan 10, 2006 Primary completion: Feb 27, 2006 Completion: Feb 27, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. 9 Meters Biopharma, Inc. leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Aug 2020 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Oct 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Oct 2017 [monthly]

Completed PHASE1

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

9 Meters Biopharma, Inc.

Data source: 9 Meters Biopharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States